Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Tongli Haiyuan Biotechnology is a specialized biotechnology company focused on providing high-quality raw materials and reagents for the cell and gene therapy (CGT) industry. The company develops and manufactures GMP-grade recombinant proteins, including essential cytokines like IL-2 and IL-15, as well as critical enzymes such as Cas9 and Benzonase. Their product portfolio also includes specialized cell culture media and magnetic beads for cell separation and activation. By maintaining rigorous quality control systems and ISO certifications, Tongli Haiyuan supports the clinical translation and commercial production of advanced biopharmaceuticals. The company serves a global clientele of pharmaceutical firms and research institutions from its headquarters in Beijing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Tongli Haiyuan Biotechnology.